Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of LY-M001 in adults with Gaucher disease type 1
CTR20241092Phase 2Active
- Sponsor
- Lingyi Biotechnology
- Start
- Aug 2024
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of LY-M001 in Gaucher disease type 1 (GD1), sponsored by Lingyi Biotechnology. Started Aug 2024; status: active.
02
Drugs
LY-M001
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on CTR20241092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241092.